Detail akcie ANI Pharmaceuticals online

Business Summary: ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Financial Summary: BRIEF: For the six months ended 30 June 2026, ANI Pharmaceuticals Inc revenues increased 23% to $503.5M. Net income applicable to common stockholders increased from $21M to $50.4M. Revenues reflect Rare Disease segment increase of 29% to $272.1M, Generics Established Brands and Other segment increase of 6% to $209.9M. Net income benefited from Unrealized gain on investment in equity increase from $589K (expense) to $6.5M (income).